Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway

[1]  T. Ahern,et al.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. , 2011, Journal of the National Cancer Institute.

[2]  Yanhong Zhang,et al.  Mutant p53 Disrupts MCF-10A Cell Polarity in Three-dimensional Culture via Epithelial-to-mesenchymal Transitions* , 2011, The Journal of Biological Chemistry.

[3]  Israel Steinfeld,et al.  miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors , 2011, PloS one.

[4]  B. Bojková,et al.  Antineoplastic effects of simvastatin in experimental breast cancer. , 2011, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[5]  A. Polotskaia,et al.  A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation , 2011, Breast Cancer Research.

[6]  A. Frigessi,et al.  In Silico Ascription of Gene Expression Differences to Tumor and Stromal Cells in a Model to Study Impact on Breast Cancer Outcome , 2010, PloS one.

[7]  T. Satou,et al.  Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway , 2010, Journal of experimental & clinical cancer research : CR.

[8]  R. Sato.  Sterol metabolism and SREBP activation. , 2010, Archives of biochemistry and biophysics.

[9]  Torben Lüders,et al.  Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density , 2010, Breast Cancer Research.

[10]  P. Boutros,et al.  Dysregulation of the mevalonate pathway promotes transformation , 2010, Proceedings of the National Academy of Sciences.

[11]  T. Sørlie,et al.  Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer , 2010, Molecular oncology.

[12]  T. Kodama,et al.  Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells. , 2010, The Biochemical journal.

[13]  C. Mandal,et al.  Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. , 2010, Cellular signalling.

[14]  I. Simon,et al.  Modulation of the vitamin D3 response by cancer-associated mutant p53. , 2010, Cancer cell.

[15]  Wensheng Yan,et al.  Characterization of Functional Domains Necessary for Mutant p53 Gain of Function*♦ , 2010, The Journal of Biological Chemistry.

[16]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[17]  A. Barsotti,et al.  Pro-proliferative FoxM1 is a target of p53-mediated repression , 2009, Oncogene.

[18]  Y. Chiba,et al.  Inhibition of geranylgeranyltransferase inhibits bronchial smooth muscle hyperresponsiveness in mice. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[19]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[20]  Jeffrey T. Chang,et al.  Utilization of Genomic Signatures to Identify Phenotype-Specific Drugs , 2009, PloS one.

[21]  Ziwei Gu,et al.  A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. , 2009, Chemistry & biology.

[22]  In vivo identification of promoter elements and transcription factors mediating activation of hepatic HMG-CoA reductase by T3. , 2009, Biochemical and biophysical research communications.

[23]  C. Prives,et al.  A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. , 2009, Genes & Development.

[24]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[25]  W. Deppert,et al.  Wild-type p53 in cancer cells: when a guardian turns into a blackguard. , 2009, Biochemical pharmacology.

[26]  F. B. Sørensen,et al.  High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  L. Esserman,et al.  Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer , 2009, Breast Cancer Research and Treatment.

[28]  Fabien Reyal,et al.  Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability , 2008, BMC Genomics.

[29]  Michael P. Snyder,et al.  Genome-Wide Occupancy of SREBP1 and Its Partners NFY and SP1 Reveals Novel Functional Roles and Combinatorial Regulation of Distinct Classes of Genes , 2008, PLoS genetics.

[30]  V. Rotter,et al.  Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy , 2008, Cell cycle.

[31]  L. Esserman,et al.  Estrogen Receptor–Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users , 2008, Cancer Epidemiology Biomarkers & Prevention.

[32]  M. Koyuturk,et al.  Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. , 2007, Cancer letters.

[33]  Genee Y. Lee,et al.  The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.

[34]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[35]  Richard M. Martin,et al.  Statins and risk of cancer: A systematic review and metaanalysis , 2007, International journal of cancer.

[36]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[37]  C. Prives,et al.  Mutant p53 gain of function: the NF-Y connection. , 2006, Cancer Cell.

[38]  E. Petricoin,et al.  Breast cancer growth prevention by statins. , 2006, Cancer research.

[39]  C. Prives,et al.  Transcriptional regulation by p53: one protein, many possibilities , 2006, Cell Death and Differentiation.

[40]  C. Grau,et al.  Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[43]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Osborne,et al.  Activation Domains from Both Monomers Contribute to Transcriptional Stimulation by Sterol Regulatory Element-binding Protein Dimers* , 2005, Journal of Biological Chemistry.

[45]  R. Fisher.  Statistical methods for research workers , 1927, Protoplasma.

[46]  M J Bissell,et al.  Microenvironmental Regulators of Tissue Structure and Function Also Regulate Tumor Induction and Progression : The Role of Extracellular Matrix and Its Degrading Enzymes , 2022 .

[47]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[48]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[49]  Henk-Jan Guchelaar,et al.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.

[50]  Yuko Ito,et al.  Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. , 2004, Carcinogenesis.

[51]  H. Mo,et al.  Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention , 2004, Experimental biology and medicine.

[52]  Katie L Stone,et al.  Lipid-lowering drug use and breast cancer in older women: a prospective study. , 2003, Journal of women's health.

[53]  G Kvalheim,et al.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  H. Shimano,et al.  p53 Activation in Adipocytes of Obese Mice* , 2003, Journal of Biological Chemistry.

[55]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[56]  Luquan Wang,et al.  Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression , 2003, Oncogene.

[57]  Mina J Bissell,et al.  The organizing principle: microenvironmental influences in the normal and malignant breast. , 2002, Differentiation; research in biological diversity.

[58]  M. Waterman,et al.  A cAMP-responsive element binding site is essential for sterol regulation of the human lanosterol 14alpha-demethylase gene (CYP51). , 2002, Molecular endocrinology.

[59]  Jun Sakakibara,et al.  SREBP-2 and NF-Y are involved in the transcriptional regulation of squalene epoxidase. , 2002, Biochemical and biophysical research communications.

[60]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[61]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[62]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[63]  V. Rotter,et al.  Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis , 2001, The EMBO journal.

[64]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[65]  T. Ugawa,et al.  YM‐53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species , 2000, British journal of pharmacology.

[66]  R. Pardi,et al.  Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein1 , 2000, The Journal of Immunology.

[67]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[68]  L. Blais,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.

[69]  A. Vasudevan,et al.  Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. , 1999, Journal of medicinal chemistry.

[70]  E. Conseiller,et al.  Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains , 1999, Oncogene.

[71]  M. Minden,et al.  Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.

[72]  J. Inoue,et al.  Multiple DNA elements for sterol regulatory element-binding protein and NF-Y are responsible for sterol-regulated transcription of the genes for human 3-hydroxy-3-methylglutaryl coenzyme A synthase and squalene synthase. , 1998, Journal of biochemistry.

[73]  K. Gibson,et al.  Characterization of the mevalonate kinase 5'-untranslated region provides evidence for coordinate regulation of cholesterol biosynthesis. , 1998, Biochemical and biophysical research communications.

[74]  O. Larsson,et al.  HMG-CoA reductase inhibitors: role in normal and malignant cells. , 1996, Critical reviews in oncology/hematology.

[75]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[76]  A. Levine,et al.  Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. , 1995, Oncogene.

[77]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[78]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[79]  M. Bissell,et al.  Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[80]  H. Buchwald.  Cholesterol inhibition, cancer, and chemotherapy , 1992, The Lancet.

[81]  P. Lipsky,et al.  Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation. , 1990, The Journal of biological chemistry.

[82]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.